Literature DB >> 11122240

T cell activation, apoptosis and cytokine dysregulation in the (co)pathogenesis of HIV and pulmonary tuberculosis (TB).

T Hertoghe1, A Wajja, L Ntambi, A Okwera, M A Aziz, C Hirsch, J Johnson, Z Toossi, R Mugerwa, P Mugyenyi, R Colebunders, J Ellner, G Vanham.   

Abstract

Immune parameters were compared in four groups of Ugandan subjects: HIV-and HIV+ adult patients with active pulmonary TB (HIV- PTB n = 38; HIV+ PTB n = 28), patients with HIV infection only (n = 26) and PPD+ healthy controls (n = 25). Compared with healthy controls, CD4 and CD8 T cells from patients with HIV and/or PTB expressed more activation markers (HLA-DR, CD38); their CD8 T cells expressed more CD95 (pre-apoptosis) and less CD28 (co-stimulatory receptor). Peripheral blood mononuclear cells (PBMC) of patients with either HIV or PTB were impaired in interferon-gamma (IFN-gamma) production upon antigenic stimulation. PTB (with or without HIV) was characterized by monocytosis, granulocytosis, increased transforming growth factor-beta 1 production and PPD-induced apoptosis. In vivo CD4 T cell depletion, in vitro increased spontaneous CD4 T cell apoptosis and defects in IFN-gamma responses upon mitogenic stimulation were restricted to HIV+ subjects (with or without PTB). Overlapping and distinctive immune alterations, associated with PTB and HIV, might explain mutual unfavourable influences of both diseases.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11122240      PMCID: PMC1905783          DOI: 10.1046/j.1365-2249.2000.01385.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  39 in total

Review 1.  The role of B7-1/B7-2:CD28/CLTA-4 pathways in the prevention of anergy, induction of productive immunity and down-regulation of the immune response.

Authors:  V A Boussiotis; G J Freeman; J G Gribben; L M Nadler
Journal:  Immunol Rev       Date:  1996-10       Impact factor: 12.988

Review 2.  The role of cytokines in the immune response to tuberculosis.

Authors:  G Kaplan; V H Freedman
Journal:  Res Immunol       Date:  1996 Oct-Dec

3.  Detection of three distinct patterns of T helper cell dysfunction in asymptomatic, human immunodeficiency virus-seropositive patients. Independence of CD4+ cell numbers and clinical staging.

Authors:  M Clerici; N I Stocks; R A Zajac; R N Boswell; D R Lucey; C S Via; G M Shearer
Journal:  J Clin Invest       Date:  1989-12       Impact factor: 14.808

4.  CD8+ T lymphocytes of patients with AIDS maintain normal broad cytolytic function despite the loss of human immunodeficiency virus-specific cytotoxicity.

Authors:  G Pantaleo; A De Maria; S Koenig; L Butini; B Moss; M Baseler; H C Lane; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205

5.  CD8+,CD38+ lymphocyte percent: a useful immunological marker for monitoring HIV-1-infected patients.

Authors:  A Mocroft; M Bofill; M Lipman; E Medina; N Borthwick; A Timms; L Batista; M Winter; C A Sabin; M Johnson; C A Lee; A Phillips; G Janossy
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1997-02-01

6.  Production of tumor necrosis factor alpha by monocytes from patients with pulmonary tuberculosis.

Authors:  T Takashima; C Ueta; I Tsuyuguchi; S Kishimoto
Journal:  Infect Immun       Date:  1990-10       Impact factor: 3.441

7.  CD8+ cells and not CD4+ T cells are hyporesponsive to CD28- and CD40L-mediated activation in HIV-infected subjects.

Authors:  J Vingerhoets; L Kestens; G Penne; H De Vuyst; M Vandenbruaene; Y Pelgrom; E Bosmans; M de Boer; A Kasran; M Azuma; R Colebunders; J L Ceuppens; G Vanham
Journal:  Clin Exp Immunol       Date:  1997-03       Impact factor: 4.330

8.  Expression of CD26 (dipeptidyl peptidase IV) on resting and activated human T-lymphocytes.

Authors:  T Mattern; W Scholz; A C Feller; H D Flad; A J Ulmer
Journal:  Scand J Immunol       Date:  1991-06       Impact factor: 3.487

9.  Low production of interferon gamma is related to disease progression in HIV infection: evidence from a cohort of 347 HIV-infected individuals.

Authors:  H Ullum; A Cozzi Lepri; K Bendtzen; J Victor; P C Gøtzsche; A N Phillips; P Skinhøj; B Klarlund Pedersen
Journal:  AIDS Res Hum Retroviruses       Date:  1997-08-10       Impact factor: 2.205

10.  Overexpression of Fas antigen on T cells in advanced HIV-1 infection: differential ligation constantly induces apoptosis.

Authors:  F Silvestris; P Cafforio; M A Frassanito; M Tucci; A Romito; S Nagata; F Dammacco
Journal:  AIDS       Date:  1996-02       Impact factor: 4.177

View more
  27 in total

1.  Impact of opportunistic Mycobacterium tuberculosis infection on the phenotype of peripheral blood T cells of AIDS patients.

Authors:  Germán Bernal-Fernández; Carlos Hermida; Patricia Espinosa-Cueto; Ana Cristina Cubilla-Tejeda; Jesús Fidel Salazar-González; Librado Ortiz-Ortiz; Rosario Leyva-Meza; Hugo Diaz-Silvestre; Raul Mancilla
Journal:  J Clin Lab Anal       Date:  2006       Impact factor: 2.352

2.  Increased frequency of regulatory T cells and T lymphocyte activation in persons with previously treated extrapulmonary tuberculosis.

Authors:  Alexandre S de Almeida; Christina T Fiske; Timothy R Sterling; Spyros A Kalams
Journal:  Clin Vaccine Immunol       Date:  2011-10-28

3.  Renal manifestations in children co-infected with HIV and disseminated tuberculosis.

Authors:  Peter J Nourse; Mark F Cotton; William D Bates
Journal:  Pediatr Nephrol       Date:  2010-04-27       Impact factor: 3.714

4.  Effects of antiretroviral therapy on immune function of HIV-infected adults with pulmonary tuberculosis and CD4+ >350 cells/mm3.

Authors:  Christina L Lancioni; C Scott Mahan; Denise F Johnson; Maria Walusimbi; Keith A Chervenak; Sophie Nalukwago; Edwin Charlebois; Diane Havlir; Harriet Mayanja-Kizza; Christopher C Whalen; W Henry Boom
Journal:  J Infect Dis       Date:  2011-04-01       Impact factor: 5.226

5.  Reactivation of latent tuberculosis in cynomolgus macaques infected with SIV is associated with early peripheral T cell depletion and not virus load.

Authors:  Collin R Diedrich; Joshua T Mattila; Edwin Klein; Chris Janssen; Jiayao Phuah; Timothy J Sturgeon; Ronald C Montelaro; Philana Ling Lin; Joanne L Flynn
Journal:  PLoS One       Date:  2010-03-10       Impact factor: 3.240

6.  Tuberculosis treatment in HIV infected Ugandans with CD4 counts>350 cells/mm reduces immune activation with no effect on HIV load or CD4 count.

Authors:  C Scott Mahan; Maria Walusimbi; Denise F Johnson; Christina Lancioni; Edwin Charlebois; Joyce Baseke; Keith A Chervenak; Roy D Mugerwa; Diane V Havlir; Harriet Mayanja-Kizza; Christopher C Whalen; W Henry Boom
Journal:  PLoS One       Date:  2010-02-22       Impact factor: 3.240

7.  Systemic immune activation and microbial translocation in dual HIV/tuberculosis-infected subjects.

Authors:  Zahra Toossi; Nicholas T Funderburg; Sohani Sirdeshmuk; Christopher C Whalen; Maria W Nanteza; Denise F Johnson; Harriet Mayanja-Kizza; Christina S Hirsch
Journal:  J Infect Dis       Date:  2013-03-11       Impact factor: 5.226

8.  Effects of tuberculosis on the kinetics of CD4(+) T cell count among HIV-infected patients who initiated antiretroviral therapy early after tuberculosis treatment.

Authors:  Nam Su Ku; Jin Ok Oh; So Youn Shin; Sun Bean Kim; Hye-won Kim; Su Jin Jeong; Sang Hoon Han; Young Goo Song; June Myung Kim; Jun Yong Choi
Journal:  AIDS Res Hum Retroviruses       Date:  2012-09-11       Impact factor: 2.205

9.  Monocyte-derived IL-5 reduces TNF production by Mycobacterium tuberculosis-specific CD4 T cells during SIV/M. tuberculosis coinfection.

Authors:  Collin R Diedrich; Joshua T Mattila; JoAnne L Flynn
Journal:  J Immunol       Date:  2013-05-20       Impact factor: 5.422

10.  Comparative analysis of mycobacterial heat shock proteins-induced apoptosis of peripheral blood mononuclear cells in sarcoidosis and tuberculosis.

Authors:  Anna Dubaniewicz; Piotr Trzonkowski; Mirosława Dubaniewicz-Wybieralska; Ada Dubaniewicz; Mahavir Singh; Andrzej Myśliwski
Journal:  J Clin Immunol       Date:  2006-03-21       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.